Skip to content
Ep. 131 - Seagen, New Modalities & Structure episode artwork

Aug 2, 2022 17 min

Ep. 131 - Seagen, New Modalities & Structure

from BioCentury This Week Hosted by BioCentury

Acquisition target Seagen has carved out such a differentiated portfolio of antibody-drug candidates that the company may not see much direct competition from other ADCs in the near term, BioCentury’s Lauren Martz says on the latest edition of the BioCentury This Week podcast. Martz and the BioCentury podcast team analyze how Seagen has built a pipeline around almost entirely first-in-class targets and assess how the latest cut of data for the company’s Padcev enfortumab vedotin-ejfv could broaden the ADC’s reach among cancer patients. Reach us by sending a text

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Ep. 131 - Seagen, New Modalities & Structure

0:00 17:50

Chapters

  1. 1:17 Seagen's First-in-Class Pipeline
  2. 6:00 New Modality Roundup
  3. 10:07 Emerging Company Spotlight: Structure Therapeutics
  4. 15:03 What's New on BioCentury.com

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BioCentury This Week?

This episode is 17 minutes long.

When was this BioCentury This Week episode published?

This episode was published on August 2, 2022.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.